Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00560391 · FLOW

Participant flow

Dasatinib in Combination With Revlimid (and Dexamethasone) · Source last updated 2016-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 15 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).
    id
    FG000
    title
    Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg
  2. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).
    id
    FG001
    title
    Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg
  3. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).
    id
    FG002
    title
    Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg
  4. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).
    id
    FG003
    title
    Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
  5. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 140 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22). Cohort includes 4 participants treated for dose -finding phase and 13 participants treated in dose expansion phase.
    id
    FG004
    title
    Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        1
      5. group Id
        FG004
        num Subjects
        2
      type
      Still on treatment
    milestones
    1. achievements
      1. comment
        Participants who received treatment
        group Id
        FG000
        num Subjects
        6
      2. comment
        Participants who received treatment
        group Id
        FG001
        num Subjects
        3
      3. comment
        Participants who received treatment
        group Id
        FG002
        num Subjects
        3
      4. comment
        Participants who received treatment
        group Id
        FG003
        num Subjects
        6
      5. comment
        Participants who received treatment
        group Id
        FG004
        num Subjects
        17
      type
      STARTED
    2. achievements
      1. comment
        Completed=off treatment;Disease progression-1;Death-1;Max. clinical benefit-2;Study drug toxicity-2
        group Id
        FG000
        num Subjects
        6
      2. comment
        Completed=off treatment; Disease progression-1;Death-1; Unrelated AE-1
        group Id
        FG001
        num Subjects
        3
      3. comment
        Completed=off treatment; Disease progression-1;Maximum clinical benefit-1; Unrelated AE-1
        group Id
        FG002
        num Subjects
        3
      4. comment
        Completed=off treatment; Disease progression-2; Unrelated AE 1 and Subject request 2
        group Id
        FG003
        num Subjects
        5
      5. comment
        Completed=offtreatment;Disease progression-6;Study drug toxicity-7; Unrelated AE-1,Subject request-1
        group Id
        FG004
        num Subjects
        15
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        1
      5. group Id
        FG004
        num Subjects
        2
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Of 39 participants were enrolled in this study, 4 never received treatment due to screening failure. A total of 35 participants received treatment.
Complete source fields
groups
  1. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 15 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).
    id
    FG000
    title
    Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg
  2. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).
    id
    FG001
    title
    Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg
  3. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).
    id
    FG002
    title
    Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg
  4. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).
    id
    FG003
    title
    Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
  5. description
    Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 140 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22). Cohort includes 4 participants treated for dose -finding phase and 13 participants treated in dose expansion phase.
    id
    FG004
    title
    Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        1
      5. group Id
        FG004
        num Subjects
        2
      type
      Still on treatment
    milestones
    1. achievements
      1. comment
        Participants who received treatment
        group Id
        FG000
        num Subjects
        6
      2. comment
        Participants who received treatment
        group Id
        FG001
        num Subjects
        3
      3. comment
        Participants who received treatment
        group Id
        FG002
        num Subjects
        3
      4. comment
        Participants who received treatment
        group Id
        FG003
        num Subjects
        6
      5. comment
        Participants who received treatment
        group Id
        FG004
        num Subjects
        17
      type
      STARTED
    2. achievements
      1. comment
        Completed=off treatment;Disease progression-1;Death-1;Max. clinical benefit-2;Study drug toxicity-2
        group Id
        FG000
        num Subjects
        6
      2. comment
        Completed=off treatment; Disease progression-1;Death-1; Unrelated AE-1
        group Id
        FG001
        num Subjects
        3
      3. comment
        Completed=off treatment; Disease progression-1;Maximum clinical benefit-1; Unrelated AE-1
        group Id
        FG002
        num Subjects
        3
      4. comment
        Completed=off treatment; Disease progression-2; Unrelated AE 1 and Subject request 2
        group Id
        FG003
        num Subjects
        5
      5. comment
        Completed=offtreatment;Disease progression-6;Study drug toxicity-7; Unrelated AE-1,Subject request-1
        group Id
        FG004
        num Subjects
        15
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        1
      5. group Id
        FG004
        num Subjects
        2
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Of 39 participants were enrolled in this study, 4 never received treatment due to screening failure. A total of 35 participants received treatment.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice